Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study.

Publisher: Hindawi Pub. Corporation Country of Publication: Egypt NLM ID: 101183692 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-2530 (Electronic) Linking ISSN: 17402522 NLM ISO Abbreviation: Clin Dev Immunol Subsets: MEDLINE

Publication: 2007- : Cario : Hindawi Pub. Corporation
Original Publication: 2003-2006: Abingdon, U.K. : Taylor & Francis Health Sciences

Idiopathic Pulmonary Fibrosis/*immunology ; RNA, Messenger/*analysis ; Sarcoidosis, Pulmonary/*immunology ; Vascular Endothelial Growth Factor A/*biosynthesis ; Vascular Endothelial Growth Factor Receptor-1/*biosynthesis; Adult ; Aged ; Aged, 80 and over ; Bronchoalveolar Lavage Fluid/chemistry ; Chemokines, CXC/biosynthesis ; Chemokines, CXC/genetics ; Female ; Humans ; Idiopathic Pulmonary Fibrosis/genetics ; Idiopathic Pulmonary Fibrosis/physiopathology ; Male ; Middle Aged ; Prospective Studies ; Sarcoidosis, Pulmonary/genetics ; Sarcoidosis, Pulmonary/physiopathology ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor Receptor-1/genetics

Background: We have previously shown a different local and systemic angiogenic profile of CXC chemokines in Idiopathic Pulmonary Fibrosis (IPF) patients compared to sarcoidosis. In particular, sarcoidosis showed an angiostatic microenvironment, as compared with the angiogenic cytokine milieu seen in IPF. Purpose of the Study. Our aim was to further investigate the aforementioned finding by measuring the expression of different chemokines in granulomatous and fibrotic diseases. We estimated the levels of vascular endothelial growth factor (VEGF) and its high-affinity receptor, Flt-1 (fms-like tyrosine kinase 1), in bronchoalveolar lavage fluid (BALF) of patients with IPF and pulmonary sarcoidosis. We have also investigated the mRNA expression of angiogenetic chemokines' receptors such as CXCR2 and CXCR3 and the biological axis of stromal derived factor-1 alpha (SDF-1 alpha or CXCL12 alpha/CXCL12 beta) and receptor, CXCR4.
Methods: We studied prospectively three groups of patients: (i) one group of 18 patients with IPF, (ii) one group of 16 patients with sarcoidosis, and (iii) 10 normal subjects.
Results: A statistically significant increase has been detected in VEGF mRNA expression in IPF in comparison with pulmonary sarcoidosis (P = .03). In addition, a significant increase has been measured in CXCL12 alpha in sarcoidosis in comparison to IPF (P = .02). Moreover, a statistically significant decrease has been found in Flt-1 protein levels in pulmonary sarcoidosis in comparison with IPF (P = .03). A significant increase in VEGF (P = .03) and CXCR4 (P = .03) mRNA levels has been also detected in sarcoidosis' patients when compared with healthy controls.
Conclusions: Our data suggest that increased expression of Flt-1 and downregulation of CXCL12 alpha in IPF may further support the hypothesis of a different angiogenetic profile between fibrotic and granulomatous diseases. However, further studies are needed in order to better investigate these enigmatic diseases.

Respirology. 2008 Mar;13(2):281-4. (PMID: 18339029)
J Exp Med. 1998 Jan 5;187(1):129-34. (PMID: 9419219)
Curr Opin Pulm Med. 2002 Sep;8(5):435-40. (PMID: 12172449)
Eur Respir J. 1998 Sep;12(3):716-38. (PMID: 9762805)
J Immunol. 1998 Dec 1;161(11):6413-20. (PMID: 9834133)
J Allergy Clin Immunol. 2001 Apr;107(4):664-70. (PMID: 11295656)
Clin Exp Immunol. 2007 Aug;149(2):317-26. (PMID: 17550373)
Cell. 1993 Mar 26;72(6):835-46. (PMID: 7681362)
Eur Respir J. 2009 Sep;34(3):676-86. (PMID: 19386686)
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. (PMID: 11790668)
Am J Respir Crit Care Med. 2004 Aug 1;170(3):207-9. (PMID: 15280169)
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1179-80. (PMID: 15161610)
J Intern Med. 2003 Dec;254(6):564-71. (PMID: 14641797)
Cytokine Growth Factor Rev. 2005 Dec;16(6):593-609. (PMID: 16046180)
Pulm Pharmacol Ther. 2008 Dec;21(6):840-4. (PMID: 18644457)
Chest. 2006 Jun;129(6):1592-8. (PMID: 16778280)
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1203-8. (PMID: 14754760)
Am J Respir Crit Care Med. 2002 Jan 15;165(2):236-41. (PMID: 11790661)
Respirology. 2006 Nov;11(6):708-14. (PMID: 17052298)
Thorax. 1963 Sep;18:225-37. (PMID: 14064617)
Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L209-21. (PMID: 16403941)
Curr Opin Pulm Med. 2008 Sep;14(5):455-61. (PMID: 18664976)
Int J Oncol. 2006 Aug;29(2):305-14. (PMID: 16820871)
Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73. (PMID: 10560120)
BMC Pulm Med. 2005 Jun 24;5:8. (PMID: 15978129)
Eur Respir J. 1989 Jun;2(6):561-85. (PMID: 2663535)
Am J Respir Crit Care Med. 2003 Feb 1;167(3):438-43. (PMID: 12406847)
Int Arch Allergy Immunol. 2005 Jul;137(3):229-35. (PMID: 15956791)
Eur Respir J Suppl. 1993 Mar;16:5-40. (PMID: 8499054)
Eur Respir J. 2002 Nov;20(5):1206-12. (PMID: 12449175)
Lung. 2003;181(5):259-65. (PMID: 14705769)
Am J Respir Crit Care Med. 2002 Aug 1;166(3):382-5. (PMID: 12153975)
J Interferon Cytokine Res. 2006 Jun;26(6):400-5. (PMID: 16734560)
Chest. 2006 Oct;130(4):982-8. (PMID: 17035428)
Chest. 2002 Dec;122(6 Suppl):298S-301S. (PMID: 12475804)

0 (Chemokines, CXC)
0 (RNA, Messenger)
0 (Vascular Endothelial Growth Factor A)
EC 2.7.10.1 (FLT1 protein, human)
EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)

Date Created: 20100220 Date Completed: 20100608 Latest Revision: 20220409

20231215

PMC2821758

10.1155/2009/537929

20169144